Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 56

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 56
---
all amounts are averages for Non-PEO NEOs). |

Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 32

The below figures are represented in thousands.

| (4) | The dollar amounts reported herein represent the average of the amounts of total compensation reported for our Non-PEO NEOs as a group for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. |

| (5) | Cumulative total stockholder return (“TSR”) assumes $100 was invested on December 31, 2022 and is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period (December 31, 2022) by our stock price at the beginning of the measurement period. At December 31, 2024, 2023 and 2022, the per share closing prices for our Ordinary Shares were $2.28, $0.60 and $0.73, respectively. No dividends were paid on share or option awards for all periods presented. |

| (6) | Net lossis reflected as reported in our audited consolidated financial statements for the applicable fiscal year. |

|                                                                                                                                                                                                                                     |     | PEO |  2024 |   |     |   | 2023 |   |     | Non-PEO NEO Average | 2024 |   |     |   | 2023 |   |
|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:----|------:|:--|:----|:--|-----:|:--|:----|:--------------------|-----:|:--|:----|:--|-----:|:--|
| Summary Compensation Table Total                                                                                                                                                                                                    |     | $   | 1,149 |   |     | $ |  950 |   |     | $                   |  485 |   |     | $ |  385 |   |
| -the fair value of equity awards granted that are reported in the Summary Compensation Table                                                                                                                                        |     |     |  (742 | ) |     |   | (532 | ) |     |                     | (246 | ) |     |   | (141 | ) |
| + Fair value as of the end of all awards granted during the covered fiscal year that are outstanding and unvested at the end of the covered year                                                                                    |